Navigation Links
Ryan & Maniskas, LLP Announces Investigation of MAP Pharmaceuticals, Inc.
Date:1/24/2013

WAYNE, Pa., Jan. 24, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/mapp) is investigating potential claims against the board of directors of MAP Pharmaceuticals, Inc. ("MAP" or the "Company") (NASDAQ: MAPP) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Allergan, Inc. in a transaction valued at approximately $958 million.

(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )

Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company's board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of MAP.  For more information regarding our investigation, please contact Ryan & Maniskas, LLP ( Richard A. Maniskas, Esquire ) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/mapp.Under the terms of the proposal, public shareholders of MAP will receive $25.00 per share in cash for each share of MAP they own.

If you own shares of MAP and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/mapp.  You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com.  For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.CONTACT:Ryan & Maniskas, LLPRichard A. Maniskas, Esquire995 Old Eagle School Rd., Suite 311Wayne, PA 19087877-316-3218www.rmclasslaw.com/cases/mapprmaniskas@rmclasslaw.com


'/>"/>
SOURCE Ryan & Maniskas, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)...   ZappRx, Inc ., a digital health company focused ... announced it closed $25 million in Series B funding led ... in Seattle that is part of ... Series B round included participation from SR One , ... GV (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Global Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, ... 2024" report to their offering. ... The global pharmacogenomics market was valued at US$ ... 11,938.8 Mn by 2024, expanding at a CAGR of 5.6% ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology:
(Date:4/30/2017)... ... April 30, 2017 , ... PracticeMatch, a company that provides healthcare recruiting resources ... year’s physician career fairs, with this year’s RSVPs and registrations so far tracking a ... year of national physician career fairs is located on the PracticeMatch website. ...
(Date:4/29/2017)... , ... April 29, 2017 , ... TransDark is a ... from one video to the next without having to set a single keyframe in ... transitions to enhance your video production. , TransDark features dynamic transitions that momentarily splits ...
(Date:4/29/2017)... ... 2017 , ... Saturday, April 29, marks World Veterinary Day, ... on animal health and welfare as well as on public health. The World ... theme each year and this year have selected “Antimicrobial Resistance—From Awareness to Action,” ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... LINCOLN, R.I. (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much ... Sleep Foundation (NSF), going just 19 hours without sleep can compromise motor reaction time, which ... Awareness Week, and Amica Insurance is sharing the following tips from the NSF to help ...
Breaking Medicine News(10 mins):